This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Intraocular Lens (IOL): Market Shares, Strategies, And Forecasts, Worldwide, Nanotechnology, 2013 To 2018

5. INTRAOCULAR LENS (IOL) - COMPANY DESCRIPTION 5-1

5.1 Abbott Laboratories 5-1 5.1.1 Abbott Acquired Visiogen with Synchrony Product 5-1 5.1.2 Abbott Labs Cataract Company Acquisitions 5-2 5.1.3 Abbott Completes Separation of Research-Based Pharmaceuticals Business 5-3 5.1.4 Abbott (NYSE: ABT) Separation Of Its Research-Based Pharmaceuticals Business 5-3 5.1.5 Abbott Separating Into Two Independent Companies 5-4 5.1.6 Abbott Laboratories and Subsidiaries Revenue 5-4 5.1.7 Abbott Sales Mix 5-6 5.1.8 Abbott Nutritional Market Presence 5-7 5.1.9 Abbott Diagnostics Market Presence 5-8 5.1.10 Abbott Medical Devices Market Presence 5-8 5.1.11 Abbott Strength Through Ability to Innovate 5-9 5.1.12 Abbott Revenue 5-10 5.1.13 Abbott Medical Optics 5-11 5.1.14 Abbott Medical Optics Corneal Products 5-11 5.1.15 Abbott Medical Optics Refractive Product Line 5-12 5.1.16 Abbott Medical Optics Cataract Products 5-12 5.1.17 Abbott Medical Optics Technological Innovation 5-12 5.2 Akkolens 5-13 5.2.1 AkkoLens Features 5-14 5.2.2 AkkoLens Clinical Partners 5-15 5.3 Allergan 5-16 5.3.1 Allergan Flagship Franchises In Eye Care, Neurosciences, Medical Dermatology And Urologics 5-17 5.3.2 Allergan Acquisition of Inamed Corporation 5-17 5.3.3 Allergan Specialty Product Lines Focused On High-Growth Markets 5-17 5.3.4 Allergan Global in reach. Specialized in focus 5-18 5.3.5 Allergan Leading Products 5-19 5.3.6 Allergan/ SkinMedica, Inc. Acquisition 5-19 5.3.7 Allergan Obesity Intervention 5-19 5.4 Aravind 5-20 5.4.1 Future of Aravind 5-21 5.5 Bausch And Lomb 5-21 5.5.1 Bausch + Lomb Vision Care 5-21 5.5.2 Bausch + Lomb Pharmaceuticals 5-22 5.5.3 Bausch + Lomb Cataract and Vitreoretinal Surgery 5-22 5.5.4 Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 5-23 5.5.5 Bausch + Lomb Technolas Perfect Vision 5-24 5.5.6 Bausch + Lomb Technolas Perfect Vision Transforming Refractive Surgery 5-25 5.5.7 Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 5-25 5.5.8 Technolas Perfect Vision 5-26 5.6 Biovision 5-26 5.7 Elenza 5-27 5.8 Kowa Company, Ltd. 5-28 Environmental & Energy Saving Products 5-29 5.9 Hoya 5-33 5.9.1 Hoya, Seiko And Epson; Agreements Executed In The Field Of Optical Products Business 5-35 5.9.2 Hoya Second Quarter Revenue 5-36 5.10 Lenstec 5-38 5.11 Novartis Group / Alcon 5-39 5.11.1 Novartis Alcon Division 5-39 5.11.2 Novartis Revenue 5-40 5.11.3 Alcon Cataract Surgery 5-42 5.11.4 Alcon Surgical Glaucoma 5-42 5.11.5 Alcon Vitreoretinal 5-43 5.11.6 Alcon Refractive Surgery 5-43 5.11.7 Alcon Acquires Leading Ocular Surgical Guidance Technology 5-43

5.11.8 Alcon 5-44

4 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs